IDEXX Laboratories Reports Director/Officer Changes & Financials

TL;DR

IDEXX leadership shuffle and financials filed. Keep an eye on executive comp.

AI Summary

IDEXX Laboratories, Inc. filed an 8-K on November 12, 2024, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits, with the earliest event reported as November 8, 2024.

Why It Matters

This filing provides updates on the company's leadership and financial reporting, which are crucial for investors to assess governance and financial health.

Risk Assessment

Risk Level: low — This is a routine 8-K filing detailing corporate governance and financial reporting, not indicating any immediate operational or financial distress.

Key Players & Entities

• IDEXX LABORATORIES, INC. (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• November 8, 2024 (date) — Earliest event reported
• November 12, 2024 (date) — Filing date

FAQ

Key Financial Figures

• $0.10 — ange on whichregistered Common Stock, $0.10 par value per share IDXX NASDAQ Glo

Filing Documents

• tm2428103d1_8k.htm (8-K) — 34KB
• tm2428103d1_ex99-1.htm (EX-99.1) — 4KB
• tm2428103d1_8kimg001.jpg (GRAPHIC) — 8KB
• 0001104659-24-116365.txt ( ) — 229KB
• idxx-20241108.xsd (EX-101.SCH) — 3KB
• idxx-20241108_lab.xml (EX-101.LAB) — 33KB
• idxx-20241108_pre.xml (EX-101.PRE) — 22KB
• tm2428103d1_8k_htm.xml (XML) — 3KB

02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b)On November 8, 2024, Jonathan W. Ayers, a member of the Board of Directors (the "Board") of IDEXX Laboratories, Inc. (the "Company"), resigned from the Board and its finance committee, effective November 8, 2024. A copy of Mr. Ayers's resignation letter is included as Exhibit 99.1 to this Current Report on Form 8-K. Mr. Ayers's decision to resign was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. Mr. Ayers served as the Company's Chairman of the Board, President and Chief Executive Officer from 2002 through 2019 and as a non-employee director from 2019 until November 8, 2024. The Company and Board thank Mr. Ayers for his more than two decades of service and leadership at the Company and are grateful for his many valuable contributions during his long tenure. In connection with Mr. Ayers's resignation, the size of the Board is being reduced from eleven to ten directors.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d)Exhibits 99.1 Resignation letter dated November 8, 2024 of Jonathan W. Ayers. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORATORIES, INC. Date: November 12, 2024 By: /s/ Sharon E. Underberg Sharon E. Underberg Executive Vice President, General Counsel and Corporate Secretary 3

View Full Filing

View this 8-K filing on SEC EDGAR